Age-Dependent Risk of Stroke and Death in Young Patients with Atrial Fibrillation: A Nationwide Cohort Study
Author
Melgaard, Line
Term
4. term
Publication year
2013
Submitted on
2013-05-31
Pages
10
Abstract
This thesis examines how the risks of stroke and death vary with age among young patients with atrial fibrillation in a nationwide cohort study. The study leverages national health registries, identifying atrial fibrillation/flutter using ICD-10 code I48. Outcomes include stroke (I60-I64), transient ischemic attack (G45, excluding G45.3), systemic embolism (I74), and mortality. Comorbidities are captured through codes for heart failure, acute myocardial infarction, hypertension, diabetes, peripheral arterial disease, renal and liver disease, mechanical heart valves, and mitral stenosis. Medication use is described with ATC codes, including oral anticoagulants (warfarin, phenprocoumon, dabigatran), antiplatelet therapy (clopidogrel), and other cardiovascular treatments (e.g., beta-blockers, calcium channel blockers, renin-angiotensin inhibitors, statins, diuretics, amiodarone, and acid-suppressive drugs). These code lists point to a registry-based design with age-stratified risk assessment and adjustment for comorbidity and treatment. Numerical results and effect estimates are not included in the provided excerpt.
Dette speciale undersøger, hvordan risikoen for apopleksi og død varierer med alderen blandt unge patienter med atrieflimren i et landsdækkende kohortestudie. Studiet anvender nationale sundhedsregistre, hvor atrieflimren/-flutter identificeres med ICD-10-koden I48. Kliniske udfald omfatter apopleksi (I60-I64), transitorisk cerebral iskæmi (G45, ekskl. G45.3), systemisk emboli (I74) og dødelighed. Komorbiditet kortlægges via koder for bl.a. hjertesvigt, akut myokardieinfarkt, hypertension, diabetes, perifer arteriesygdom, nyre- og leversygdom samt mekaniske hjerteklapper og mitralstenose. Lægemiddelbrug beskrives med ATC-koder, herunder orale antikoagulantia (warfarin, phenprocoumon, dabigatran), trombocythæmmere (clopidogrel) og andre kardiovaskulære behandlinger (fx betablokkere, calciumantagonister, renin-angiotensin-hæmmere, statiner, diuretika, amiodaron og mavesyrehæmmere). Kodelisterne indikerer et registerbaseret design med aldersopdelte risikovurderinger og justering for komorbiditet og behandling. De faktiske resultater og effektstørrelser fremgår ikke af det udleverede uddrag.
[This apstract has been generated with the help of AI directly from the project full text]